Singapore, June 25 -- Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company, has entered into a strategic partnership agreement with Amoy Diagnostics and PREMIA Holdings (HK) Ltd.

Under the agreement, AmoyDx and PREMIA will provide large-scale cancer patient screening in Asia to support the ongoing clinical development of LOXO-292, Loxo Oncology's RET (rearranged during transfection) kinase inhibitor which leverages AmoyDx's proprietary multi-gene polymerase chain reaction (PCR) and next generation sequencing (NGS) panels to identify patients with this rare genetic alteration.

Wenn Sun, founder and president of PREMIA and Li-Mou Zheng, founder and chief executive officer of AmoyDx said, "We are extremely pleased to ann...